Natural, innate improvements in multiple sclerosis disability

被引:22
作者
Tremlett, Helen [1 ]
Zhu, Feng [2 ]
Petkau, John [2 ]
Oger, Joel [1 ]
Zhao, Yinshan [1 ]
机构
[1] Univ British Columbia, Fac Med, Div Neurol, Vancouver, BC V6T 2B5, Canada
[2] Univ British Columbia, Dept Stat, Vancouver, BC V6T 2B5, Canada
基金
加拿大健康研究院;
关键词
Multiple sclerosis; disease progression; disability; improvement; natural history; innate improvement; RATING NEUROLOGIC IMPAIRMENT; DIAGNOSTIC-CRITERIA; HISTORY; DISEASE; INTERRATER; GUIDELINES;
D O I
10.1177/1352458512439119
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Improvements in multiple sclerosis (MS) disability have recently been reported in immunomodulatory drug (IMD) clinical trials and observational studies. However, improvements have rarely been examined in natural history or IMD naive patients. We investigated annual and biennial improvements in Expanded Disability Status Scale (EDSS) scores in British Columbia, Canada. Methods: The British Columbian MS database was accessed for definite MS patients (1980-2009). Consecutive IMD-free EDSS scores one and two years apart (+/- 3 months) were examined; improvements (>= 0.5,>= 1,>= 2 EDSS points) and sustained improvements (confirmed at one year) were described. The influence of patient characteristics on improvements was examined using logistic regression. Results: From 16,132 EDSS scores, 7653 yearly and 5845 biennial EDSS intervals were available for 2961 and 2382 patients respectively. Of the yearly intervals, 14.9% showed an improvement (>= 0.5 points), 8.3% >= 1 point and 2.2% >= 2 point improvement, with nearly half being sustained. Corresponding worsenings were observed in 32.9%, 20.5% and 7.9% respectively, with stability in just over half (53%). Biennial findings were similar. Characteristics generally associated with improvements included: female sex, younger age, shorter disease duration, relapsing-onset and presence of moderate disability (compared with mild or advanced) and a previous episode of worsening (disassociated from a relapse). However, improvements were also observed after periods of stability and in primary-progressive MS. Conclusion: Improvements in MS disability over one or two years are not unusual. We suggest the term 'innate improvements'. Our findings have implication for the design of clinical trials and observational studies in MS targeting improvements on the EDSS.
引用
收藏
页码:1412 / 1421
页数:10
相关论文
共 32 条
[1]   Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator [J].
Boggild, Mike ;
Palace, Jackie ;
Barton, Pelham ;
Ben-Shlomo, Yoav ;
Bregenzer, Thomas ;
Dobson, Charles ;
Gray, Richard .
BRITISH MEDICAL JOURNAL, 2009, 339 :1359-1363
[2]   Oral versus Intravenous Steroids for Treatment of Relapses in Multiple Sclerosis [J].
Burton, J. M. ;
O'Connor, P. W. ;
Hohol, M. ;
Beyene, J. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (03)
[3]   Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes [J].
Coles, Alasdair J. ;
Fox, Edward ;
Vladic, Anton ;
Gazda, Suzanne K. ;
Brinar, Vesna ;
Selmaj, Krzysztof W. ;
Doan-Do Bass, Ann ;
Wynn, Daniel R. ;
Margolin, David H. ;
Lake, Stephen L. ;
Moran, Susan ;
Palmer, Jeffrey ;
Smith, M. Shelton ;
Compston, D. Alastair S. .
LANCET NEUROLOGY, 2011, 10 (04) :338-348
[4]   ESTABLISHMENT AND USE OF MULTIPLE-SCLEROSIS REGISTERS - EDMUS [J].
CONFAVREUX, C .
ANNALS OF NEUROLOGY, 1994, 36 :S136-S139
[5]   The natural history of multiple sclerosis: a geographically based study - 5. The clinical features and natural history of primary progressive multiple sclerosis [J].
Cottrell, DA ;
Kremenchutzky, M ;
Rice, GPA ;
Koopman, WJ ;
Hader, W ;
Baskerville, J ;
Ebers, GC .
BRAIN, 1999, 122 :625-639
[6]   Disability as an outcome in MS clinical trials [J].
Ebers, G. C. ;
Heigenhauser, L. ;
Daumer, M. ;
Lederer, C. ;
Noseworthy, J. H. .
NEUROLOGY, 2008, 71 (09) :624-631
[7]   AN ASSESSMENT OF DISABILITY RATING-SCALES USED IN MULTIPLE-SCLEROSIS [J].
FRANCIS, DA ;
BAIN, P ;
SWAN, AV ;
HUGHES, RAC .
ARCHIVES OF NEUROLOGY, 1991, 48 (03) :299-301
[8]   INTERRATER AND INTRARATER SCORING AGREEMENT USING GRADES 1.0 TO 3.5 OF THE KURTZKE EXPANDED DISABILITY STATUS SCALE (EDSS) [J].
GOODKIN, DE ;
COOKFAIR, D ;
WENDE, K ;
BOURDETTE, D ;
PULLICINO, P ;
SCHEROKMAN, B ;
WHITHAM, R ;
JACOBS, L ;
MUNSCHAUER, F ;
EMRICH, L ;
GRANGER, C ;
HERNDON, R ;
RUDICK, R ;
FISCHER, J ;
SIMON, J ;
SALAZAR, A .
NEUROLOGY, 1992, 42 (04) :859-863
[9]   COPOLYMER-1 REDUCES RELAPSE RATE AND IMPROVES DISABILITY IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - RESULTS OF A PHASE-III MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
JOHNSON, KP ;
BROOKS, BR ;
COHEN, JA ;
FORD, CC ;
GOLDSTEIN, J ;
LISAK, RP ;
MYERS, LW ;
PANITCH, HS ;
ROSE, JW ;
SCHIFFER, RB ;
VOLLMER, T ;
WEINER, LP ;
WOLINSKY, JS ;
BIRD, SJ ;
CONSTANTINESCU, C ;
KOLSON, DL ;
GONZALEZSCARANO, F ;
BRENNAN, D ;
PFOHL, D ;
MANDLER, RN ;
ROSENBERG, GA ;
JEFFREY, C ;
BARGER, GR ;
GANDHI, B ;
MOORE, PM ;
ROGERS, LR ;
LISAK, D ;
SMITH, L ;
ELLISON, GW ;
BAUMHEFNER, RW ;
CRAIG, SL ;
JALBUT, SS ;
KATZ, E ;
CONWAY, KL ;
BURNS, JB ;
SHIBA, C ;
GIANG, DW ;
PETRIE, MD ;
GUARNACCIA, JB ;
ANDERSON, S ;
MCKEON, A ;
MCCARTHY, M ;
THOMAS, AB ;
VRIESENDORP, FJ ;
AUSTIN, SG ;
LINDSEY, JW ;
DIMACHKIE, M ;
CERRETA, E ;
KACHUCK, N ;
MCCARTHY, KA .
NEUROLOGY, 1995, 45 (07) :1268-1276
[10]   Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity [J].
Jones, Joanne L. ;
Anderson, Jane M. ;
Phuah, Chia-Ling ;
Fox, Edward J. ;
Selmaj, Krzysztof ;
Margolin, David ;
Lake, Stephen L. ;
Palmer, Jeffrey ;
Thompson, Sara J. ;
Wilkins, Alastair ;
Webber, Daniel J. ;
Compston, D. Alastair ;
Coles, Alasdair J. .
BRAIN, 2010, 133 :2232-2247